Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities

Rhea-AI Summary

Inotiv (NASDAQ: NOTV) announced a strategic collaboration with VUGENE on December 11, 2025 to integrate VUGENE’s cloud-based AI/ML multi-omics bioinformatics platform into Inotiv’s Discovery & Translational Sciences Division.

The partnership aims to accelerate AI-assisted drug discovery by improving interpretation of epigenomic, proteomic, and other molecular datasets to better predict drug efficacy and safety in early-stage research. Inotiv said the integration will enable more efficient, data-driven decision making for client discovery programs, while VUGENE expects broader application of its computational technologies in real-world research settings.

Market Reality Check

$0.7642 Last Close

Volume Volume 233,774 is 0.15x the 20-day average of 1,587,782 shares. low

Technical Shares at 0.8414 are trading below the 200-day MA of 1.87 and 87.02% under the 52-week high.

Peers on Argus 1 Down

Sector peers show mixed moves, with ADVB down 9.61% and others modestly up or down. With only one peer in momentum and no shared news, the AI-focused partnership appears company-specific rather than part of a sector-wide move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 03	Earnings report	Positive	+8.1%	Reported FY2025 revenue growth and sharply reduced operating loss.
Nov 25	Growth ranking	Positive	+3.9%	Ranked 182nd on Deloitte Technology Fast 500 with 448% growth.
Nov 21	Earnings date notice	Neutral	-3.9%	Announced timing and access details for FY2025 results call.
Nov 17	Preliminary results	Positive	-33.2%	Shared preliminary FY2025 revenue and strong DSA growth metrics.
Oct 21	Conference participation	Neutral	-2.2%	Outlined participation in multiple November investor conferences.

Pattern Detected

Operationally positive news has sometimes aligned with gains but also seen sharp selloffs, indicating inconsistent market confidence in updates.

Recent Company History

Over the last few months, Inotiv reported improving FY2025 results with Q4 revenue of $138.1M and FY revenue of $513.0M, alongside a narrowed operating loss of $30.9M. Recognition on the 2025 Deloitte Technology Fast 500™ and strong DSA growth, with backlog around $138M, highlight expansion. However, preliminary results on Nov 17, 2025 coincided with a -33.2% move, contrasting with the later earnings-day gain of 8.13%. Today’s AI partnership adds to a pattern of strategic initiatives amid volatile reactions.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-08-29

An effective S-3 shelf filed on 2025-08-29 allows future securities offerings, including an at-the-market equity program with up to 3.0% commission. The filing highlights an auditor’s explanatory paragraph raising substantial doubt about going-concern status, material weaknesses in internal control, and warns of immediate dilution risk and variable ATM proceeds.

Market Pulse Summary

This announcement details a strategic collaboration integrating VUGENE’s AI-enabled bioinformatics platform into Inotiv’s Discovery & Translational Sciences Division to better analyze complex epigenomic and proteomic data. It follows FY2025 revenue of $513.0M and recognition in the 2025 Deloitte Technology Fast 500™. Regulatory filings, including the 2025-08-29 S-3, highlight going-concern language, internal-control weaknesses, and dilution risk. Investors may watch how this AI partnership translates into Discovery and Safety Assessment growth and backlog trends.

Key Terms

contract research organization technical

"a leading Contract Research Organization (CRO) specializing in nonclinical"

A contract research organization (CRO) is an outside company hired to run medical and scientific work for drug, device or biotech developers—like an experienced project manager and lab team that companies rent instead of building in-house. Investors care because CROs influence development speed, quality and cost: delays or successes in trials affect client spending, regulatory risk and ultimately revenues for both the sponsor and the CRO.

multi-omics medical

"VUGENE, a multi-omics data analysis company providing advanced"

Multi-omics is a comprehensive approach that combines different types of biological data—such as genetic information, proteins, and other molecules—to gain a detailed understanding of how living systems function. For investors, this approach can reveal insights into health, disease, or biological processes that may influence the development of new treatments or technologies, potentially impacting market opportunities and innovation in healthcare.

artificial intelligence technical

"providing advanced artificial intelligence (AI) and machine learning (ML)"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

machine learning technical

"artificial intelligence (AI) and machine learning (ML) solutions for"

Machine learning is a set of computer programs that learn patterns from large amounts of data and improve their predictions or decisions over time, like a recipe that gets better each time it’s adjusted based on taste tests. For investors it matters because these systems can speed up analysis, spot trends or risks humans might miss, automate routine work, and potentially create competitive advantages or cost savings that affect a company’s performance.

bioinformatics medical

"cloud-based bioinformatics and computational platform into its Discovery"

The use of computer tools and data analysis to organize and interpret large biological datasets, such as DNA, protein or patient information. It matters to investors because it speeds up research, lowers development costs and helps identify promising drug targets, diagnostics or personalized treatments—think of it as using GPS and analytics to find the fastest, most reliable route through vast amounts of lab data.

epigenomic medical

"interpret the full spectrum of epigenomic, proteomic, and other"

The epigenomic describes the pattern of chemical tags and markers across a cell’s DNA that control which genes are turned on or off, like sticky notes on a recipe book guiding what gets cooked. For investors, epigenomic changes are important because they can reveal new drug targets, diagnostics, or ways to predict and treat disease, affecting a biotech’s product pipeline, regulatory path, and long-term market value.

proteomic medical

"full spectrum of epigenomic, proteomic, and other molecular datasets"

Proteomic describes something related to the large-scale study of proteins—the working parts inside cells that carry out functions and signal changes. For investors, proteomic work can reveal new drug targets, diagnostic tests or biomarkers that change a company’s potential revenue and risk profile; think of it like analyzing all ingredients in a recipe to find which ones can be improved or swapped to make a better product.

AI-generated analysis. Not financial advice.

WEST LAFAYETTE, Ind., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization (CRO) specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, and VUGENE, a multi-omics data analysis company providing advanced artificial intelligence (AI) and machine learning (ML) solutions for biomedical research, today announced a strategic collaboration designed to accelerate AI-assisted drug discovery and enhance data-driven insights across the drug development continuum.

Through this partnership, Inotiv will integrate VUGENE’s cloud-based bioinformatics and computational platform into its Discovery & Translational Sciences Division, enabling a more efficient and intelligent analysis of complex biological data. The collaboration will enhance Inotiv’s ability to interpret the full spectrum of epigenomic, proteomic, and other molecular datasets, with the goal of ultimately improving the prediction of drug efficacy and safety in early-stage research.

“To maximize the value of our clients’ discovery programs, we must efficiently integrate and interpret complex datasets,” said Scott Daniels, PhD, Senior Vice President of Drug Discovery & Translational Sciences at Inotiv. “VUGENE’s AI-enabled bioinformatics platform gives our team a powerful tool to advance data-driven, AI-assisted discovery, helping clients make faster, more informed decisions.”

For VUGENE, the partnership is an opportunity to expand the reach and application of its computational technologies within real-world research environments.

“Inotiv’s integrated approach to drug discovery, specifically their focus on the qualification of new target biology and disease modeling, makes them an ideal partner,” said Juozas Gordevičius, PhD, Founder and CTO of VUGENE. “Together we can combine advanced multi-omics bioinformatics and AI with experimental expertise to accelerate scientific breakthroughs and improve human health.”

About Inotiv

Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotiv.com/.

About VUGENE

VUGENE is a global multi-omics data analysis and interpretation company. The VUGENE platform enables the elucidation of disease mechanisms and therapeutic mode-of-action, assisting in the discovery and development of novel treatments. The VUGENE platform integrates biological data from multiple sources including tissue and cellular sources and range from (epi)genomics, transcriptomics, proteomics and metabolomics.

This release contains "forward-looking statements," within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified with words such as “aim”, “anticipate”, “assume”, “believe”, “could”, “estimate”, “expect”, “future”, “goal”, “intend”, “likely”, “may”, “plan”, “project”, “seek”, “strategy”, “target”, “will” and similar expressions. Forward-looking statements in this release include, but are not limited to, statements regarding the Company’s new strategic collaboration, including the workings of the collaboration and its expected effects, impacts and results, potential expansions and additional innovation, and commitments to new approach methodologies and their expected effects, impacts and results. These forward-looking statements are not statements of historical facts and represent only the Company’s current expectations regarding such matters. All forward-looking statements are subject to significant risks, uncertainties and changes in circumstances that could cause actual results and outcomes to differ materially from those expressed or implied in the forward-looking statements, including, but are not limited to, those detailed in the Company's filings with the U.S. Securities and Exchange Commission. Further discussion of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in the Company’s Annual Report on Form 10-K as filed on December 4, 2024, as well as other filings with the Securities and Exchange Commission. Except to the extent required by law, the Company does not undertake, and expressly disclaims, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise. 

Company Contact		Investor Relations
Inotiv, Inc.		LifeSci Advisors
Beth A. Taylor, Chief Financial Officer		Steve Halper
(765) 497-8381		(646) 876-6455
beth.taylor@inotiv.com		shalper@lifesciadvisors.com

FAQ

What did Inotiv (NOTV) announce on December 11, 2025 about VUGENE?

Inotiv announced a strategic collaboration to integrate VUGENE’s cloud-based AI/ML multi-omics bioinformatics platform into its Discovery & Translational Sciences Division.

How will the Inotiv and VUGENE partnership affect early-stage drug research for NOTV clients?

The integration aims to improve interpretation of epigenomic, proteomic, and molecular data to help predict drug efficacy and safety and speed client decision making.

Does the Inotiv (NOTV) release specify financial terms or revenue impact from the VUGENE deal?

No. The announcement does not disclose financial terms, revenue guidance, or quantified financial impacts.

What technologies is VUGENE providing to Inotiv (NOTV)?

VUGENE is providing a cloud-based bioinformatics and computational platform using AI and machine learning for multi-omics data analysis.

Will the Inotiv and VUGENE collaboration change Inotiv’s service offerings for NOTV customers?

Inotiv says the partnership will enhance its ability to analyze complex biological datasets and support more data-driven, AI-assisted discovery for clients.

When did Inotiv (NOTV) announce the VUGENE collaboration?

The collaboration was announced on December 11, 2025.